SCHEMBL22872802

SCHEMBL22872802

CC(C)CCCCCCCCNC(=O)CN(C)CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.39
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MEN1 O00255 2/20 0.38
KDM4C Q9H3R0 2/20 0.37
KDM4A O75164 1/20 0.37
PHF8 Q9UPP1 1/20 0.37
KDM2A Q9Y2K7 1/20 0.37
CASP2 P42575 1/20 0.37
EPHX1 P07099 2/20 0.37
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.35
HIF1A Q16665 1/20 0.35
NAAA Q02083 1/20 0.35
TP53 P04637 1/20 0.35
DNM1 Q05193 1/20 0.35
HPGD P15428 1/20 0.35
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23589671 1.00 NAMPT (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL23589714 1.00 NAMPT (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL23589692 1.00 NAMPT (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL23589907 1.00 NAMPT (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL23589715 1.00 NAMPT (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22301097 0.98 KMT2A (0.39) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL23589720 0.93 SMN1; SMN2 (0.37) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL22872801 0.90 KMT2A (0.37) NAMPTKMT2AALDH1A1SMN1; SMN2MEN1
SCHEMBL25101472 0.89 CASP2 (0.51) KMT2AMEN1CASP2EPHX1NAAA
SCHEMBL21227614 0.89 CASP2 (0.51) KMT2AMEN1CASP2EPHX1NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 US disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 US disclosed
US-20210009568-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS FOGHORN THERAPEUTICS INC. 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773085-B2 Methods and compounds for treating disorders VHL, TFEB, BECN1 NAMPT 1207/4885KMT2A 583/4885ALDH1A1 2034/4885
US-20210009568-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS VHL, TFEB, BECN1 NAMPT 1207/4885KMT2A 583/4885ALDH1A1 2034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.